{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:38:43Z","timestamp":1790908723063,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.nano.2013.10.009","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T18:00:59Z","timestamp":1383588059000},"page":"755-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats"],"prefix":"10.1016","volume":"10","author":[{"given":"Ying-Zheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Rong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.nano.2013.10.009_bb0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.10.009_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1567201053586047","article-title":"Intranasal drug delivery for brain targeting","volume":"2","author":"Vyas","year":"2005","journal-title":"Current Drug Delivery"},{"issue":"3","key":"10.1016\/j.nano.2013.10.009_bb0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/03639040802360510","article-title":"Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir","volume":"35","author":"Alsarra","year":"2009","journal-title":"Drug Development and Industrial Pharmacy"},{"issue":"5","key":"10.1016\/j.nano.2013.10.009_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10717540802035251","article-title":"Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation","volume":"15","author":"Alsarra","year":"2008","journal-title":"Drug Delivery"},{"issue":"3","key":"10.1016\/j.nano.2013.10.009_bb0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","article-title":"A study of rivastigmine liposomes for delivery into the brain through intranasal route","volume":"58","author":"Arumugam","year":"2008","journal-title":"Acta Pharma"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0250-474X.41456","article-title":"Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles","volume":"70","author":"Doijad","year":"2008","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2000.7483","article-title":"Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra","volume":"166","author":"Howells","year":"2000","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.nano.2013.10.009_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001756-199902250-00021","article-title":"Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra","volume":"10","author":"Parain","year":"1999","journal-title":"NeuroReport"},{"key":"10.1016\/j.nano.2013.10.009_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.43.2.372","article-title":"Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease","volume":"43","author":"Tooyama","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-8993(94)91378-1","article-title":"Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease","volume":"656","author":"Tooyama","year":"1994","journal-title":"Brain Res"},{"issue":"26","key":"10.1016\/j.nano.2013.10.009_bb0065","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1523\/JNEUROSCI.4601-04.2005","article-title":"Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta","volume":"25","author":"Baquet","year":"2005","journal-title":"The Journal of Neuroscience"},{"issue":"3","key":"10.1016\/j.nano.2013.10.009_bb0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1523\/JNEUROSCI.4493-06.2007","article-title":"Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion","volume":"27","author":"Timmer","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.nano.2013.10.009_bb0255","series-title":"Progress in Brain Research","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0079-6123(10)84013-0","article-title":"Chapter 13 \u2014 neurotrophic factor therapy for Parkinson's disease","volume":"184","author":"Rangasamy","year":"2010"},{"issue":"12","key":"10.1016\/j.nano.2013.10.009_bb0080","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","article-title":"Transport of brain-derived neurotrophic factor across the blood\u2013brain barrier","volume":"37","author":"Pan","year":"1998","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.nano.2013.10.009_bb0085","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1073\/pnas.90.4.1513","article-title":"Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition","volume":"90","author":"Edelman","year":"1993","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1007570509232","article-title":"Blood\u2013brain barrier transport of 125I-labeled basic fibroblast growth factor","volume":"17","author":"Deguchi","year":"2000","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/08977198909029125","article-title":"The fate of intravenously administered bFGF and the effect of heparin","volume":"1","author":"Whalen","year":"1989","journal-title":"Growth Factors"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1023\/A:1011922819926","article-title":"Stealth PLA-PEG nanoparticles as protein carriers for nasal administration","volume":"15","author":"Tob\u00edo","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2013.10.009_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10837450903013568","article-title":"Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design","volume":"15","author":"Varshosaz","year":"2010","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"10.1016\/j.nano.2013.10.009_bb0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/08982100903443065","article-title":"Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability","volume":"20","author":"Varshosaz","year":"2010","journal-title":"Journal of Liposome Research"},{"key":"10.1016\/j.nano.2013.10.009_bb0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neuroscience.2010.10.054","article-title":"Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats","volume":"172","author":"Jiang","year":"2011","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.nano.2013.10.009_bb0120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.burns.2011.01.018","article-title":"Preparation and characterisation of bFGF-encapsulated liposomes and evaluation of wound-healing activities in the rat","volume":"37","author":"Xiang","year":"2011","journal-title":"Burns"},{"issue":"8","key":"10.1016\/j.nano.2013.10.009_bb0125","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat \u03b1-synuclein model of Parkinson's disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.nano.2013.10.009_bb0130","doi-asserted-by":"crossref","first-page":"e38837","DOI":"10.1371\/journal.pone.0038837","article-title":"Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein","volume":"7","author":"Kemeny","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2004.02.010","article-title":"Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats","volume":"58","author":"van den Berg","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2008.09.030","article-title":"Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia","volume":"446","author":"Wang","year":"2008","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.nano.2013.10.009_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2009.05.002","article-title":"Nanotechnological applications for the treatment of neurodegenerative disorders","volume":"88","author":"Modi","year":"2009","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.nano.2013.10.009_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/714044316","article-title":"Preparation and characterization of solid lipid nanoparticles containing cloricromene","volume":"10","author":"Bond\u00ec","year":"2003","journal-title":"Drug Delivery"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12249-010-9563-0","article-title":"Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery","volume":"12","author":"Das","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.nano.2013.10.009_bb0160","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/1061186X.2010.523787","article-title":"Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route","volume":"19","author":"Patel","year":"2011","journal-title":"J Drug Target"},{"issue":"6","key":"10.1016\/j.nano.2013.10.009_bb0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/jps.2600840609","article-title":"Effect of surfactants on the physical stability of recombinant human growth hormone","volume":"84","author":"Katakam","year":"1995","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2013.10.009_bb0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.colsurfb.2012.05.010","article-title":"Phospholipid based colloidal poloxamer\u2013nanocubic vesicles for brain targeting via the nasal route","volume":"100","author":"Salama","year":"2012","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.10.009_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0378-5173(00)00681-5","article-title":"Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies","volume":"215","author":"Vandelli","year":"2001","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.nano.2013.10.009_bb0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00592-011-0356-z","article-title":"Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy","volume":"49","author":"Zhao","year":"2012","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.nano.2013.10.009_bb0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jps.21043","article-title":"Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues","volume":"97","author":"Di Colo","year":"2008","journal-title":"J Pharm Sci"},{"issue":"4\u20135","key":"10.1016\/j.nano.2013.10.009_bb0190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejps.2007.08.006","article-title":"Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties","volume":"32","author":"Zaki","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0195","first-page":"105","article-title":"Animal models for intranasal drug delivery studies. A review article","volume":"2","author":"Gizurarson","year":"1990","journal-title":"Acta Pharmaceutica Nordica"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.10.009_bb0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2006.08.043","article-title":"Enhancing effect of surfactants on fexofenadine\u00b7HCl transport across the human nasal epithelial cell monolayer","volume":"330","author":"Lin","year":"2007","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.nano.2013.10.009_bb0205","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s11095-008-9550-2","article-title":"Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model","volume":"25","author":"Charlton","year":"2008","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.nano.2013.10.009_bb0215","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.10.009_bb0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.nano.2013.10.009_bb0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0006-8993(93)90312-B","article-title":"Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging","volume":"621","author":"Date","year":"1993","journal-title":"Brain Res"},{"issue":"17","key":"10.1016\/j.nano.2013.10.009_bb0230","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1523\/JNEUROSCI.4922-05.2006","article-title":"Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1\/2 and phosphatidylinositol-3 kinase pathways","volume":"26","author":"Hsuan","year":"2006","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.nano.2013.10.009_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nm0195-53","article-title":"Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease","volume":"1","author":"Takayama","year":"1995","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/j.nano.2013.10.009_bb0240","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/S0735-1097(00)00988-8","article-title":"Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study","volume":"36","author":"Laham","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.nano.2013.10.009_bb0245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/03639045.2011.604331","article-title":"Physical characterization and cellular uptake of propylene glycol liposomes in vitro","volume":"38","author":"Zhang","year":"2012","journal-title":"Drug Development and Industrial Pharmacy"},{"issue":"2","key":"10.1016\/j.nano.2013.10.009_bb0250","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1471-4159.1987.tb04106.x","article-title":"Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury","volume":"48","author":"Altar","year":"1987","journal-title":"J Neurochem"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963413005856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963413005856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T02:24:30Z","timestamp":1539224670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963413005856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1549963413005856"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2013.10.009","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2013.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}